Literature DB >> 16372531

KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview.

M A Jakupec1, V B Arion, S Kapitza, E Reisner, A Eichinger, M Pongratz, B Marian, N Graf von Keyserlingk, B K Keppler.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16372531     DOI： 10.5414/cpp43595

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  13 in total

Review 1.  Ruthenium-based chemotherapeutics: are they ready for prime time?

Authors:  Emmanuel S Antonarakis; Ashkan Emadi
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-06       Impact factor: 3.333

2.  Synthesis, structure and biological evaluation of ruthenium(III) complexes of triazolopyrimidines with anticancer properties.

Authors:  Marzena Fandzloch; Liliana Dobrzańska; Tomasz Jędrzejewski; Julia Jezierska; Joanna Wiśniewska; Iwona Łakomska
Journal:  J Biol Inorg Chem       Date:  2019-11-18       Impact factor: 3.358

3.  Mitochondria are the primary target in the induction of apoptosis by chiral ruthenium(II) polypyridyl complexes in cancer cells.

Authors:  Jin-Quan Wang; Ping-Yu Zhang; Chen Qian; Xiao-Juan Hou; Liang-Nian Ji; Hui Chao
Journal:  J Biol Inorg Chem       Date:  2013-11-28       Impact factor: 3.358

4.  Studies of the Antiproliferative Activity of Ruthenium (II) Cyclopentadienyl-Derived Complexes with Nitrogen Coordinated Ligands.

Authors:  Virtudes Moreno; Julia Lorenzo; Francesc X Aviles; M Helena Garcia; João P Ribeiro; Tânia S Morais; Pedro Florindo; M Paula Robalo
Journal:  Bioinorg Chem Appl       Date:  2010-06-20       Impact factor: 7.778

Review 5.  Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.

Authors:  Sabine H van Rijt; Peter J Sadler
Journal:  Drug Discov Today       Date:  2009-09-24       Impact factor: 7.851

6.  Synthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine.

Authors:  Chandima S K Rajapakse; Alberto Martínez; Becky Naoulou; Andrzej A Jarzecki; Liliana Suárez; Christiane Deregnaucourt; Véronique Sinou; Joseph Schrével; Elgilda Musi; Grazia Ambrosini; Gary K Schwartz; Roberto A Sánchez-Delgado
Journal:  Inorg Chem       Date:  2009-02-02       Impact factor: 5.165

7.  Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation.

Authors:  Darren Griffith; Sara Cecco; Ennio Zangrando; Alberto Bergamo; Gianni Sava; Celine J Marmion
Journal:  J Biol Inorg Chem       Date:  2008-05       Impact factor: 3.358

Review 8.  New applications of old metal-binding drugs in the treatment of human cancer.

Authors:  Sara M Schmitt; Michael Frezza; Qing Ping Dou
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

9.  Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles.

Authors:  Gabriel E Büchel; Anatolie Gavriluta; Maria Novak; Samuel M Meier; Michael A Jakupec; Olesea Cuzan; Constantin Turta; Jean-Bernard Tommasino; Erwann Jeanneau; Ghenadie Novitchi; Dominique Luneau; Vladimir B Arion
Journal:  Inorg Chem       Date:  2013-05-09       Impact factor: 5.165

10.  Cytotoxic effects of the compound cis-tetraammine(oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells.

Authors:  Flávia de Castro Pereira; Aliny Pereira de Lima; Cesar Augusto Sam Tiago Vilanova-Costa; Wanessa Carvalho Pires; Alessandra de Santana Braga Barbosa Ribeiro; Lucas Carlos Gomes Pereira; Luiz Alfredo Pavanin; Wagner Batista Dos Santos; Elisângela de Paula Silveira-Lacerda
Journal:  Springerplus       Date:  2014-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.